DVAX Dynavax Technologies Corp

Price (delayed)

$7.80

Market cap

$893.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.62

Enterprise value

$1.03B

Sector: Healthcare
Industry: Biotechnology

Highlights

DVAX's revenue has surged by 195% year-on-year and by 156% since the previous quarter
The company's gross profit has surged by 161% QoQ
DVAX's quick ratio is down by 38% YoY but it is up by 19% QoQ

Key stats

What are the main financial stats of DVAX
Market
Shares outstanding
114.59M
Market cap
$893.79M
Enterprise value
$1.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.86
Price to sales (P/S)
7.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.64
Earnings
Revenue
$118.97M
EBIT
-$42.71M
EBITDA
-$35.77M
Free cash flow
-$23.97M
Per share
EPS
-$0.62
Free cash flow per share
-$0.21
Book value per share
$0.88
Revenue per share
$1.06
TBVPS
$4.36
Balance sheet
Total assets
$490.12M
Total liabilities
$390.36M
Debt
$213.68M
Equity
$99.76M
Working capital
$318.11M
Liquidity
Debt to equity
2.14
Current ratio
3.91
Quick ratio
2.9
Net debt/EBITDA
-3.76
Margins
EBITDA margin
-30.1%
Gross margin
71.5%
Net margin
-51.9%
Operating margin
-17.3%
Efficiency
Return on assets
-16.2%
Return on equity
-86.4%
Return on invested capital
-9.2%
Return on capital employed
-11.2%
Return on sales
-35.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DVAX stock price

How has the Dynavax Technologies stock price performed over time
Intraday
6.41%
1 week
-20.49%
1 month
-23.08%
1 year
85.71%
YTD
75.28%
QTD
-20.65%

Financial performance

How have Dynavax Technologies's revenue and profit performed over time
Revenue
$118.97M
Gross profit
$85.08M
Operating income
-$20.53M
Net income
-$61.75M
Gross margin
71.5%
Net margin
-51.9%
DVAX's revenue has surged by 195% year-on-year and by 156% since the previous quarter
The company's gross profit has surged by 161% QoQ
The company's operating margin has surged by 94% YoY and by 88% QoQ
Dynavax Technologies's net margin has soared by 83% YoY and by 68% from the previous quarter

Growth

What is Dynavax Technologies's growth rate over time

Valuation

What is Dynavax Technologies stock price valuation
P/E
N/A
P/B
8.86
P/S
7.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.64
DVAX's EPS has soared by 64% YoY and by 17% from the previous quarter
Dynavax Technologies's equity has soared by 70% from the previous quarter
DVAX's P/B is 26% below its 5-year quarterly average of 11.2 and 18% below its last 4 quarters average of 10.1
DVAX's revenue has surged by 195% year-on-year and by 156% since the previous quarter
The P/S is 98% less than the 5-year quarterly average of 406.7 and 51% less than the last 4 quarters average of 14.1

Efficiency

How efficient is Dynavax Technologies business performance
The ROE has soared by 88% YoY and by 43% from the previous quarter
DVAX's ROS has soared by 86% YoY and by 70% from the previous quarter
Dynavax Technologies's ROA has soared by 65% YoY and by 30% from the previous quarter
Dynavax Technologies's return on invested capital has surged by 65% YoY and by 28% QoQ

Dividends

What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DVAX.

Financial health

How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 26% higher than its total liabilities
Dynavax Technologies's total assets has surged by 89% YoY and by 39% QoQ
The company's total liabilities has surged by 58% YoY and by 33% QoQ
Dynavax Technologies's debt is 114% more than its equity
The debt to equity has plunged by 88% YoY and by 42% from the previous quarter
Dynavax Technologies's equity has soared by 70% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.